ERBB2 and breast cancer: As an attempt to de-escalate systemic therapy for HER2+ BC, the adjuvant paclitaxel trastuzamab (APT) trial evaluated upfront surgery (mastectomy or lumpectomy) followed by adjuvant paclitaxel + trastuzumab for 12 weeks and trastuzumab for a total of 1 year in patients with T1-2N0-N1mic HER2+ BC23,24.